{"id":"fosd","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Arrhythmias"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"736aeea3-f206-454d-95d0-fd30964e8aab","title":"NULIBRY (FOSDENOPTERIN HYDROBROMIDE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [SENTYNL THERAPEUTICS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting phosphodiesterase 3, FosD prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to increased cAMP concentrations in vascular smooth muscle and cardiac tissue. This results in vasodilation, reduced peripheral vascular resistance, and positive inotropic effects, improving hemodynamics in heart failure and cardiogenic shock.","oneSentence":"FosD is a phosphodiesterase 3 (PDE3) inhibitor that increases intracellular cAMP levels to promote vasodilation and improve cardiac contractility.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:38:55.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute decompensated heart failure"},{"name":"Cardiogenic shock"}]},"trialDetails":[{"nctId":"NCT01167868","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-07","conditions":"Healthy","enrollment":56},{"nctId":"NCT01608542","phase":"PHASE1","title":"A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Healthy Japanese Volunteers","enrollment":24},{"nctId":"NCT01197781","phase":"PHASE1","title":"Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Drug Drug Interactions, Healthy Volunteers","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FosD","genericName":"FosD","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FosD is a phosphodiesterase 3 (PDE3) inhibitor that increases intracellular cAMP levels to promote vasodilation and improve cardiac contractility. Used for Acute decompensated heart failure, Cardiogenic shock.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}